Coatings for promoting endothelization of medical devices

• US 20090043380A1
• Filed: 05/28/2008
• Published: 02/12/2009
• Est. Priority Date: 08/09/2007
• Status: Abandoned Application

• Current Assignee: PLS Technologies, LLC
• Original Assignee: Specialized Vascular Technologies, Inc.
• Inventors: Blaha, Charles Matthew, Phan, Loc X., To, John
• Application Number:
  US12/128,533
• Publication Number:
  US 20090043380A1
• Time in Patent Office: Days
• US Class Current: 623/1.460
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/114 Nitric oxide, i.e. NO
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

A unique method and coatings are provided for promoting tissue encapsulation of medical devices, especially before antiproliferative drug therapy within a body of a patient in order to prevent excessive restenosis and while avoiding thrombosis (including late stage/stent thrombosis). The method involves delaying the activation of restenosis suppressing (i.e. antiproliferative) drugs in the vicinity of the medical device until a thin layer of geometrically streamlined tissue has deposited itself upon the device. Coatings of one or more layer that provide an aligned scaffolding (i.e. via aligned fibers or aligned grooves) may be used in the method to encourage tissue deposition and/or to delay elution of drug(s) stored beneath or within. The delay phase prior to degradation, erosion, and/or absorption of the coating to release an active drug should last until an optimal amount of controlled restenosis has provided a thin endothelial layer to encapsulate the device.

Claims

1. A coating, on a medical device, configured to promote formation of a protective matrix layer of a body'"'"'s own tissue in situ and in vivo.

2. The coating of claim 1, on a drug eluting medical device, configured for delaying onset of elution of a restenosis suppressing drug until the device has been encapsulated by a thin layer of the body'"'"'s own tissue, wherein the coating promotes tissue encapsulation, encourages tissue proliferation, and facilitates controlled restenosis.

3. The coating of claim 2, comprising a combination of a biodegradable, hydrophilic barrier adjacent to one or more site of drug storage and a biodegradable, slightly hydrophobic barrier adjacent to the hydrophilic barrier.

4. The coating of claim 3, wherein the hydrophilic barrier comprises at least one element selected from the group consisting of:

dextran, polyvinyl alcohol, polyethylene glycol (PEG, also known as poly(ethylene oxide) (PEO) or polyoxyethylene (POE)), gelatin, pullulan, heparin, hirudin, ticlopidine, chlopidogrel, a salt, and an anticoagulant.

5. The coating of claim 3, wherein the slightly hydrophobic barrier comprises at least one element selected from the group consisting of:

polylactide, polylactic acid, polyglycolide, polyglycolic acid, polylactide-polyglycolide, polycaprolactone, polyamino acid and any copolymer of the aforementioned elements.

6. The coating of claim 3, comprising at least two layers, wherein one layer comprises the hydrophilic barrier and a separate layer comprises the slightly hydrophobic barrier.

7. The coating of claim 3, wherein the hydrophilic barrier is distributed in pockets within the hydrophobic barrier which forms a matrix or coating.

8. The coating of claim 7, wherein the hydrophobic barrier matrix or coating has a higher viscosity than the hydrophilic barrier pockets.

9. The coating of claim 7, wherein the hydrophilic barrier pockets repel the drug.

10. The coating of claim 7, wherein the hydrophilic barrier pockets absorb water quickly upon degradation of the hydrophobic barrier matrix or coating to form a low viscosity solution to facilitate drug elution.

11. The coating of claim 10, wherein absorption of water by the hydrophilic barrier pockets upon initial degradation of the hydrophobic barrier matrix or coating causes water to flood the hydrophobic barrier, inducing its hydrolysis and accelerating further degradation of the hydrophobic barrier.

12. The coating of claim 7, wherein the hydrophilic barrier consists of dextran and the hydrophobic barrier consists of 75% polylactic acid and 25% polyglycolic acid.

13. The coating of claim 1, comprising aligned fibers.

14. The coating of claim 1, comprising aligned grooves.

15. The coating of claim 13, wherein the medical device is a stent.

16. The coating of claim 14, wherein the medical device is a stent.

17. The coating of claim 2, further comprising a second coating wherein the second coating is a protective coating.

18. The coating of claim 13, wherein the aligned fibers are nanofibers or microfibers having diameters from 0.5 to 10 microns wide and having lengths at least twice the size of the diameters.

19. The coating of claim 14, wherein the aligned grooves are nanogrooves or microgrooves having diameters from 0.5 to 10 microns wide and having lengths at least twice the size of the diameters.

20. The coating of claim 13, wherein the fibers comprise a nitric oxide functional group and release nitric oxide as they degrade.

21. The coating of claim 18, wherein the aligned fibers are oriented at an angle of 0 to 30 degrees relative to a long axis of the medical device.

22. The coating of claim 19, wherein the aligned grooves are oriented at an angle of 0 to 30 degrees relative to a long axis of the medical device.

23. The coating of claim 13, wherein the aligned fibers are positioned on an inner surface, or a luminal wall, of the medical device and are aligned approximately parallel to a long axis of the medical device.

24. The coating of claim 13, wherein the aligned fibers are positioned on an outer surface, or an abluminal wall, of the medical device and are aligned approximately parallel to a long axis of the medical device.

25. The coating of claim 13, wherein the fibers form an artificial endothelium that aligns both blood flow and growth of endothelial cells in a uniform direction to facilitate rapid development of a functional endothelium.

26. The coating of claim 25, wherein the functional endothelium is a one cell layer that inhibits proliferation of smooth muscle, also termed restenosis, by releasing nitric oxide.

27. The coating of claim 15, wherein the stent has struts, and the aligned fibers are only positioned on inner and outer surfaces of the struts of the stent.

28. The coating of claim 15, wherein the stent has struts, and the aligned fibers cross at least two struts of the stent.

29. The coating of claim 1, wherein the coating is biodegradable, bioabsorbable, or bioerodable.

30. The coating of claim 29, further comprising a layer of aligned fibers, wherein the layer of aligned fibers is nonbiodegradable, nonbioabsorbable, and nonbioerodable.

31. The coating of claim 1, wherein the coating is sufficiently elastomeric such that it conforms to a lumen in which the medical device is inserted to close any gaps between the device and the lumen in order to avoid stagnant pockets that could cause a thrombus to develop.

32. The coating of claim 1, further comprising a layer adjacent to the coating, wherein the layer comprises at least one anti-thrombogenic substance.

33. The coating of claim 1, further comprising an anti-thrombogenic substance.

34. The coating of claim 1, further comprising a layer adjacent to the coating, wherein the layer comprises at least one therapeutic agent for reducing clotting, selected from the group consisting of:

heparin, ticlopidine, chlopidrel, enoxaparin, dalteparin, hirudin, dextran , bivalirudin, argatroban, danparoid, tissue factor pathway inhibitor (TFPI), a GPVI antagonist, an antagonist to a platelet adhesion receptor (GP1b-V-IX), and an antagonist to a platelet aggregation receptor (GPIIb-IIIa).

35. The coating of claim 1, further comprising at least one therapeutic agent for reducing clotting, selected from the group consisting of:

heparin, ticlopidine, chlopidrel, enoxaparin, dalteparin, hirudin, dextran , bivalirudin, argatroban, danparoid, tissue factor pathway inhibitor (TFPI), a GPVI antagonist, an antagonist to a platelet adhesion receptor (GP1b-V-IX), and an antagonist to a platelet aggregation receptor (GPIIb-IIIa).

36. The coating of claim 1, further comprising a layer adjacent to the coating, wherein the layer comprises at least one endothelization promoting substance.

37. The coating of claim 36, wherein the endothelization promoting substance is selected from the group consisting of:

vascular endothelial growth factor (VEGF), an antibody to CD34 receptors, angiopoietin-1, and phosphorylcholine.

38. The coating of claim 1, further comprising at least one endothelization promoting substance selected from the group consisting of:

vascular endothelial growth factor (VEGF), an antibody to CD34 receptors, angiopoietin-1, and phosphorylcholine.

39. The coating of claim 1, further comprising a low density lipoprotein and/or a high density lipoprotein.

40. The coating of claim 1, wherein the medical device is a stent having struts, and the coating completely degrades in an amount of time it takes for the stent struts to be covered with intimal cells.

41. The coating of claim 2, wherein an amount of time for delaying onset of elution of the restenosis suppressing drug is from 5 days to 60 days.

42. The coating of claim 41, wherein the amount of time for delaying onset of elution of the restenosis suppressing drug is from 7 days to 45 days.

43. The coating of claim 42, wherein the amount of time for delaying onset of elution of the restenosis suppressing drug is from 15 to 30 days.

44. The coating of claim 41, wherein the amount of time for delaying onset of elution corresponds to:

an amount of time it takes for at least one drug-containing or drug-covering layer to degrade; and

an amount of time it takes for most of the medical device to become covered by a thin layer of cells produced by endothelization and/or restenosis.

45. The coating of claim 41, wherein the medical device is a stent having struts on its inside (or luminal surface) and further comprising more than one layer, wherein all layers collectively form the coating;

wherein the coating layers are arranged from the stent struts to an outermost surface of the stent in the following order;

(i) a primer layer;

(ii) a layer comprising at least one antiproliferative or immunosuppressant drug; and

(iii) a layer for delaying an onset of release of the antiproliferative or immunosuppressant drug.

70. The coating of claim 2, wherein the restenosis suppressing drug is selected from the group consisting of:

paclitaxel, rapamycin, sirolimus, everolimus, biolimus, zotarolimus, tacrolimus, fibroblast growth factor (bFGF), rapamycin analogs, antisense dexamethasone, angiopeptin, Batimistat™

, Translast™

, Halofuginon™

, acetylsalicylic acid, Tranilast™

, hirudin, steroids, ibuprofen, antimicrobials, antibiotics (including actinomycin D), tissue plasma activators, estradiol, and agents that affect VSMC (vascular smooth muscle cell) proliferation or migration (including transcription factor E2F1).

46. A stent for implantation in a narrowed region of a blood vessel is coated with:

(i) a primer layer;

(ii) a layer comprising at least one antiproliferative or immunosuppressant drug; and

(iii) a layer comprising aligned elements for delaying an onset of release of the antiproliferative or immunosuppressant drug, wherein the aligned elements are selected from the group consisting of;

nanofibers, microfibers, nanogrooves, microgrooves, and any combination of the aforementioned elements.

47. A method for delaying activation of an antiproliferative or an immunosuppressant drug around a medical device implanted within a body until after:

(i) 5-60 days have elapsed from medical device implantation; and

(ii) the medical device has been encapsulated by a thin layer of the body'"'"'s own tissue.

48. The method of claim 47, wherein delaying activation is achieved at least in part by delaying elution of the drug from within the medical device, by providing a coating or a matrix, wherein the coating or the matrix degrades, erodes, and/or is absorbed by the body to expose the drug.

49. The method of claim 48, wherein the coating or the matrix comprises aligned fibers aligned grooves, or a combination of aligned fibers and aligned grooves.

50. The method of claim 49, wherein if there are fibers, at least some of the fibers are nanofibers, microfibers, or a combination of thereof or if there are grooves, at least some of the grooves are nanogrooves, microgrooves, or a combination thereof.

51. The method of claim 49, wherein the fibers or the grooves comprise a nitric oxide functional group and release nitric oxide as they degrade, erode, and/or are absorbed.

52. The method of claim 49, wherein the coating or the matrix further comprises at least one hydrophobic substance that breaks down quickly in a hydrophobic environment as provided by restenotic material.

53. The method of claim 52, further comprising a hydrophilic barrier positioned adjacent to the drug.

54. The method of claim 53, wherein the hydrophilic barrier comprises at least one element selected from the group consisting of:

dextran, polyvinyl alcohol, polyethylene glycol (PEG, also known as poly(ethylene oxide) (PEO) or polyoxyethylene (POE)), gelatin, pullulan, heparin, chlopidogrel, a salt, and an anticoagulant.

55. The method of claim 53, wherein the hydrophobic substance comprises at least one element selected from the group consisting of:

polylactide, polylactic acid, polyglycolide, polyglycolic acid, polylactide-polyglycolide, polycaprolactone, polyamino acid, and any copolymer of the aforementioned elements.

56. The method of claim 53, wherein the hydrophilic barrier is distributed in pockets within the hydrophobic coating or matrix.

57. The method of claim 56, wherein the hydrophobic coating or matrix has a higher viscosity than the hydrophilic barrier pockets.

58. The method of claim 56, wherein the hydrophilic barrier pockets repel the drug.

59. The method of claim 56, wherein the hydrophilic barrier pockets absorb water quickly upon degradation of the hydrophobic coating or matrix to form a low viscosity solution to facilitate drug elution.

60. The method of claim 59, wherein absorption of water by the hydrophilic barrier pockets upon initial degradation of the hydrophobic barrier coating or matrix causes water to flood the hydrophobic barrier, inducing its hydrolysis and accelerating further degradation of the hydrophobic barrier.

61. The method of claim 53, wherein the hydrophilic barrier consists of dextran and the hydrophobic coating or matrix consists of 75% polylactic acid and 25% polyglycolic acid.

62. The method of claim 47, wherein the drug is bound to a molecule that inactivates the drug until restenosis factors are present.

63. The method of claim 48, wherein the degradation, erosion, and/or absorption of the coating or the matrix is triggered by a restenosis factor selected from the group consisting of:

a hormone, an enzyme, and a peptide.

64. The method of claim 48, wherein the degradation, erosion, and/or absorption of the coating or the matrix is triggered by a pH change accompanying restenosis.

65. The method of claim 48, wherein the degradation, erosion, and/or absorption of the coating or the matrix is triggered by a pressure change, beneath the coating or within the matrix, accompanying restenosis.

66. The method according to claim 48, wherein said coating or said matrix promotes endothelization by its geometry or by exposing blood to at least one endothelization promoting substance.

67. The method according to claim 48, wherein said coating or said matrix suppresses thrombus formation by its geometry or by exposing blood to one or more substance that suppresses thrombus formation.

68. A method of coating a drug eluting stent with tissue in vivo by intentionally allowing restenosis around the stent until a thin layer of tissue coats the stent.

69. The method according to claim 68, wherein the step of allowing restenosis is achieved by delaying release of one or more drug that would prevent restenosis from occurring over the drug eluting stent.